Phase II trial of nivolumab in combination with talazoparib in patients with unresectable or metastatic melanoma and mutations in BRCA or BRCA-ness

被引：0
|
作者：
Isaacs, James
Sussman, Tamara A.
Kennedy, Lucy B.
Arbesman, Joshua
Gastman, Brian
Zhou, Millennia
Zabor, Emily
Diaz-Montero, Claudia
Ko, Jennifer
Funchain, Pauline
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT261
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT261
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase II trial of nivolumab in combination with talazoparib in unresectable or metastatic melanoma patients with mutations in BRCA or BRCAness.
    Sussman, Tamara A.
    Wei, Wei
    Hobbs, Brian
    Diaz-Montero, C. Marcela
    Ni, Ying
    Arbesman, Joshua
    Ko, Jennifer S.
    Gastman, Brian
    Funchain, Pauline
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Phase II trial on nivolumab in patients with unresectable or metastatic mucosal melanoma
    Nomura, M.
    Andoh, M.
    Yokota, T.
    Miyazaki, T.
    Satake, H.
    Iwasawa, S.
    Sonoda, A.
    Kato, K.
    Muto, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma
    Nomura, Motoo
    Oze, Isao
    Masuishi, Toshiki
    Yokota, Tomoya
    Satake, Hironaga
    Iwasawa, Shunichiro
    Kato, Ken
    Andoh, Masashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 972 - 977
  • [4] Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
    Weber, J. S.
    Muramatsu, T.
    Hamid, O.
    Mehnert, J.
    Hodi, F. S.
    Krishnarajapet, S.
    Malatyali, S.
    Buchbinder, E.
    Goldberg, J.
    Sullivan, R.
    Faries, M.
    Mehmi, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S869 - S869
  • [5] Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma
    Motoo Nomura
    Isao Oze
    Toshiki Masuishi
    Tomoya Yokota
    Hironaga Satake
    Shunichiro Iwasawa
    Ken Kato
    Masashi Andoh
    International Journal of Clinical Oncology, 2020, 25 : 972 - 977
  • [6] Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
    Jing Xu
    Tanya E. Keenan
    Beth Overmoyer
    Nadine M. Tung
    Rebecca S. Gelman
    Karleen Habin
    Judy E. Garber
    Leif W. Ellisen
    Eric P. Winer
    Paul E. Goss
    Beow Y. Yeap
    Bruce A. Chabner
    Steven J. Isakoff
    Breast Cancer Research and Treatment, 2021, 189 : 641 - 651
  • [7] Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
    Xu, Jing
    Keenan, Tanya E.
    Overmoyer, Beth
    Tung, Nadine M.
    Gelman, Rebecca S.
    Habin, Karleen
    Garber, Judy E.
    Ellisen, Leif W.
    Winer, Eric P.
    Goss, Paul E.
    Yeap, Beow Y.
    Chabner, Bruce A.
    Isakoff, Steven J.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 641 - 651
  • [8] Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial
    Tas, F
    Argon, A
    Camlica, H
    Topuz, E
    MELANOMA RESEARCH, 2005, 15 (06) : 543 - 548
  • [9] Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study
    Ferrucci, Pier F.
    Minchella, Ida
    Mosconi, Massimo
    Gandini, Sara
    Verrecchia, Francesco
    Cocorocchio, Emilia
    Passoni, Claudia
    Pari, Chiara
    Testori, Alessandro
    Coco, Paola
    Munzone, Elisabetta
    MELANOMA RESEARCH, 2015, 25 (03) : 239 - 245
  • [10] Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer
    Vidula, Neelima
    Horick, Nora
    Basile, Erin
    Blouch, Erica
    Ellisen, Leif W.
    Rugo, Hope S.
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
12345